DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zavesca (Miglustat) - Summary



Zavesca (miglustat capsules, 100 mg) is an inhibitor of the enzyme glucosylceramide synthase, which is a glucosyl transferase enzyme responsible for the first step in the synthesis of most glycosphingolipids. Zavesca is an N-alkylated imino sugar, a synthetic analog of D-glucose. The chemical name for miglustat is 1,5-(butylimino)-1,5-dideoxy-D-glucitol with the chemical formula C10H21NO4 and a molecular weight of 219.28.

Type 1 Gaucher Disease

Zavesca® is a glucosylceramide synthase inhibitor indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to allergy, hypersensitivity, or poor venous access).

See all Zavesca indications & dosage >>


Media Articles Related to Zavesca (Miglustat)

Gaucher disease may protect against Parkinson's disease-related color visual impairment
Source: Eye Health / Blindness News From Medical News Today [2015.11.11]
Parkinson's Disease (PD) patients have a five-fold greater risk of carrying genetic mutations in the β-glucocerebrosidase gene (GBA), which are commonly associated with Gaucher disease (GD).

Cerdelga Approved for Gaucher Disease
Source: MedicineNet Gaucher Disease Specialty [2014.08.21]
Title: Cerdelga Approved for Gaucher Disease
Category: Health News
Created: 8/20/2014 2:35:00 PM
Last Editorial Review: 8/21/2014 12:00:00 AM

more news >>

Published Studies Related to Zavesca (Miglustat)

Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study. [2011.11]
OBJECTIVE: To evaluate the efficacy and safety of oral miglustat treatment in patients with mucopolysaccharidosis type III. The primary outcome was efficacy with improvement or stabilization in at least two domains of Vineland Adaptative Behavior Scales at 6 months. The secondary outcome measured the evolution of other cognitive tests at 12 months. The safety and tolerability were assessed throughout the study... CONCLUSION: Miglustat treatment was not associated with any improvement/stabilization in behavior problems in patients with mucopolysaccharidosis type III. Miglustat has an acceptable safety profile. However, the study has confirmed that miglustat is able to pass through the blood-brain barrier without significantly decreasing ganglioside levels. Copyright (c) 2011 Mosby, Inc. All rights reserved.

Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. [2010.04]
A randomized, controlled trial of miglustat indicated that miglustat (Zavesca) stabilized neurological disease over 12 months in adult and juvenile patients with Niemann-Pick disease type C (NP-C).Overall, these data suggest that long-term miglustat therapy stabilizes neurological disease and is well tolerated in adult and juvenile patients with NP-C.

Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. [2009.06]
PURPOSE: To evaluate the safety and efficacy of miglustat in patients with GM2 gangliosidosis... CONCLUSION: Miglustat treatment was not shown to lead to measurable benefits in this cohort of patients with late-onset Tay-Sachs disease. The observed safety profile was consistent with that of the approved dose (100 mg TID) in type 1 Gaucher disease.

Randomized, controlled trial of miglustat in Gaucher's disease type 3. [2008.11]
OBJECTIVE: To evaluate the efficacy and safety of miglustat, concomitant with enzyme replacement therapy (ERT), in patients with Gaucher's disease type 3 (GD3)... INTERPRETATION: Miglustat does not appear to have significant benefits on the neurological manifestations of GD3. However, miglustat may have positive effects on systemic disease (pulmonary function and chitotriosidase activity) in addition to ERT in patients with GD3.

Miglustat: a review of its use in Niemann-Pick disease type C. [2014]
Miglustat (Zavesca®, Brazaves®), a small iminosugar molecule that reversibly inhibits glycosphingolipid synthesis, is the only disease-specific drug approved for the treatment of progressive neurological manifestations of Niemann-Pick disease type C (NP-C) in adult and paediatric patients... In the absence of a cure, miglustat is a valuable agent to reduce the progression of clinically relevant neurological symptoms in paediatric and adult patients with NP-C, which is considered a significant achievement in the treatment of this disease.

more studies >>

Clinical Trials Related to Zavesca (Miglustat)

A Pilot Study of Zavesca� in Patients With Pompe Disease and Infusion Associated Reaction [Recruiting]
Hypothesis: the effectiveness of treatment of Pompe disease with rhGAA enzyme replacement therapy (ERT) is limited at least in part because patients develop antibodies against the provided rhGAA enzyme. Treatment with Zavesca prior to infusion may dampen or eliminate the anti-rhGAA immune response in patients receiving ERT, thereby allowing for greater ERT efficacy. Treatment with Zavesca before a enzyme replacement therapy (ERT) may decrease the severity of, or eliminate infusion associated reactions (IAR) in people with Pompe Disease receiving ERT.

Miglustat in Niemann-Pick Type C Disease [Completed]
This is a phase II randomized controlled study of miglustat in adult and juvenile patients with Niemann-Pick Type C disease. Up to 42 patients will be randomised in a 2: 1 ratio to either treatment with miglustat or to a non-treatment group. Both groups will follow an identical visit schedule.

Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation [Recruiting]
The purpose of this study is to demonstrate that Miglustat restores the function of the cystic fibrosis transmembrane conductance regulator (CFTR) in adult patients with cystic fibrosis homozygous for the F508del mutation.

Pharmacokinetics and Tolerability of Zavesca� (Miglustat) In Patients With Juvenile GM2 Gangliosidosis [Active, not recruiting]
The purpose of the study is to investigate the pharmacokinetics of Zavesca (miglustat, OGT918) when given as single and multiple doses in juvenile patients with GM2 gangliosidosis.

Application of Miglustat in Patients With Niemann-Pick Type C [Completed]

more trials >>

Reports of Suspected Zavesca (Miglustat) Side Effects

Diarrhoea (23)Weight Decreased (20)Niemann-Pick Disease (14)Tremor (14)Condition Aggravated (13)Convulsion (10)Pneumonia (9)Dysphagia (9)Disease Progression (8)Growth Retardation (8)more >>

Page last updated: 2015-11-11

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015